PDRN CarePDRN Research Timeline
Key milestones in PDRN research — from early laboratory characterization to global clinical adoption.
1986
1986
First Characterization of PDRN
researchItalian researchers first characterize polydeoxyribonucleotide as a distinct pharmacological entity, documenting its ability to stimulate cell proliferation in vitro. Early studies focus on nucleotide metabolism and the salvage pathway.
1999
1999
Discovery of A2A Receptor Mechanism
researchLandmark research identifies the adenosine A2A receptor as the primary molecular target of PDRN, providing a mechanistic explanation for its tissue-regenerative effects. This discovery shifts PDRN from empirical therapy to evidence-based medicine.
2003
2003
PDRN Approved for Wound Healing in Italy
regulatoryItalian regulatory authorities approve PDRN-based products for clinical use in wound healing, particularly for diabetic and ischemic ulcers. Mastelli and other Italian pharmaceutical companies begin commercial production.
2010
2010
Pharmaresearch Products Founded in South Korea
industryPharmaresearch Products Co., Ltd. is established in South Korea, beginning development of salmon-derived PDRN products specifically designed for aesthetic medicine applications.
2014
2014
Rejuran Healer Launches in South Korea
product-launchPharmaresearch Products launches Rejuran Healer, the first PDRN product marketed specifically as a skin booster for aesthetic rejuvenation. The product receives MFDS approval and quickly gains popularity in Korean dermatology clinics.
2018
2018
PDRN Skin Boosters Expand Across Asia
industryRejuran and other PDRN skin boosters expand rapidly into markets across Southeast Asia, Hong Kong, and Japan. The treatment becomes a hallmark of Korean aesthetic medicine and a driver of medical tourism to Seoul.
2021
2021
European PN/PDRN Market Emerges
industryItalian manufacturers including Promoitalia (Nucleofill) and Mastelli (Plinest) gain significant market traction in Europe with polynucleotide and PDRN products, establishing a European counterpart to the Korean PDRN aesthetic market.
2025
2025
Global Consensus Guidelines Published
researchAn international panel of dermatologists and aesthetic physicians publishes the first consensus guidelines on PDRN and polynucleotide therapy, standardizing treatment protocols, product classification, and clinical evidence requirements for the growing global market.